Other

Repurposed Therapeutics, Inc

Abraxis Bioscience, LLC

Epiomed Therapeutics, Inc.

David Reed Helton

Ernest H Pfadenhauer

David Brian Fick

James Lucot

Jason Paul Sharp

A method of treating exposure to organophosphate agents and preventing morbidity due to such exposure through the administration of a triptan compound to a subject.

Treatment of organophosphate exposure with triptans

A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition.

Emesis treatment

A method of treating exposure to organophosphate agents and preventing morbidity due to such exposure through the administration of a pyrazolopyrimidine compound such as ocinaplon, zaleplon, indiplon, or divaplon.

Treatment of organophosphate exposure with ocinaplon

A method of treating exposure to an organophosphate compound by administering a cyproheptadine compound to a subject in need thereof.

Use of cyproheptadine to treat organophosphate exposure

A method of treating or preventing emesis through the administration of an effective dosage of a 2-(amino)tetralin compound in which one of the S or R enantiomers of the 2-(amino) tetralin compound is present in the composition in excess of the other enantiomer, and compositions comprising such a 2-(amino)tetralin compound in which the ratio of the S and R enantiomers is at least 2:1.

A screening method for identifying compounds with anti-emetic properties by evaluating binding affinity and efficacy of the compounds with respect to the 5-HT, 5-HT, and 5-HTreceptors.

Assay for determination of compounds having anti-emetic activity

Compositions comprising tetrahydroindolone derivatives in which the tetrahydroindolone moiety is covalently linked to a substituted arylpiperazine moiety and methods for treating neurological and psychiatric conditions using such compositions are disclosed.

Growing community of inventors

Dana Point, CA, United States of America

David Reed Helton